Nupathe: Corporate Presentation (NuPathe) - Sep 19, 2013 - Anticipated patent expiry in US for transdermal methods and systems for the delivery of anti-migraine compounds in Apr 2027; Anticipated patent expiry in US for polyamine formulation in Apr 2029; Anticipated patent expiry in US for pharmacokinetics of iontophoretic sumatriptan administration in Apr 2027; Anticipated patent expiry in US for self-contained, wearable iontophoretic devices in Feb 2023; Anticipated patent expiry for electronic controls and safety in 2032; Anticipated patent expiry for co-packaging system for iontophoretic delivery system in 2032; Anticipated patent expiry for pad detection system in 2032; Anticipated patent expiry for methods of iontophoretically treating nausea & migraine in 2032
Anticipated patent expiry • Migraine
|